Characteristics of patients within the study
| Population characteristics . | Value . | Percentage . |
|---|---|---|
| Total number in cohort | 107 | |
| Patient age, median (range), y | 56 (19-73) | |
| Patients >60 y | 44 | 41 |
| Patient sex (male) | 69 | 64 |
| CMV at risk (−/+) | 39 | 36 |
| Disease | ||
| Myeloid (AML, CML, MDS, MF) | 67 | 63 |
| Lymphoid (ALL) | 14 | 13 |
| Non-Hodgkin lymphoma | 19 | 18 |
| Hodgkin lymphoma | 7 | 7 |
| Conditioning regimen | ||
| Full intensity | ||
| Cyclo/TBI | 14 | 13 |
| Reduced intensity | ||
| Flu/Melph | 53 | 50 |
| FLAMSA/Bu | 14 | 13 |
| Flu/Bu | 12 | 11 |
| BEAM | 11 | 10 |
| Flu/BEAM | 3 | 3 |
| T-cell depletion | ||
| Alemtuzumab | 79 | 74 |
| ATG | 28 | 26 |
| Donor characteristics | ||
| Donor age, median (range), y | 48 (21-66) | |
| Donor sex (male) | 70 | 65 |
| Female donor to male patient | 22 | 21 |
| Donor type | ||
| Matched sibling (10/10) | 27 | 25 |
| Matched unrelated donor (10/10) | 70 | 65 |
| Mismatched unrelated donor (9/10) | 10 | 9 |
| Population characteristics . | Value . | Percentage . |
|---|---|---|
| Total number in cohort | 107 | |
| Patient age, median (range), y | 56 (19-73) | |
| Patients >60 y | 44 | 41 |
| Patient sex (male) | 69 | 64 |
| CMV at risk (−/+) | 39 | 36 |
| Disease | ||
| Myeloid (AML, CML, MDS, MF) | 67 | 63 |
| Lymphoid (ALL) | 14 | 13 |
| Non-Hodgkin lymphoma | 19 | 18 |
| Hodgkin lymphoma | 7 | 7 |
| Conditioning regimen | ||
| Full intensity | ||
| Cyclo/TBI | 14 | 13 |
| Reduced intensity | ||
| Flu/Melph | 53 | 50 |
| FLAMSA/Bu | 14 | 13 |
| Flu/Bu | 12 | 11 |
| BEAM | 11 | 10 |
| Flu/BEAM | 3 | 3 |
| T-cell depletion | ||
| Alemtuzumab | 79 | 74 |
| ATG | 28 | 26 |
| Donor characteristics | ||
| Donor age, median (range), y | 48 (21-66) | |
| Donor sex (male) | 70 | 65 |
| Female donor to male patient | 22 | 21 |
| Donor type | ||
| Matched sibling (10/10) | 27 | 25 |
| Matched unrelated donor (10/10) | 70 | 65 |
| Mismatched unrelated donor (9/10) | 10 | 9 |
“CMV at risk (−/+)” indicates CMV seronegative patient receiving stem cell graft from a CMV seropositive donor. Alemtuzumab dose: 50 mg (10 mg per day for 5 days). ATG dose: FLAMSA/Bu, 1 mg/kg for 1 day, then 2 mg/kg for 2 days; Flu/Bu, 2.5 mg/kg for 2 days.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BEAM, BCNU etoposide Ara-C melphalan; Bu, busulfan; CML, chronic myeloid leukemia; CMV, cytomegalovirus; Cyclo, cyclophosphamide; FLAMSA, fludarabine, Ara-C, and amsacrine; Flu, fludarabine; MDS, myelodysplastic syndrome; Melph, melphalan; MF, myelofibrosis; TBI, total body irradiation.